Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A clinical study of rhG-CSF (KRN8601) in patients with
myelodysplastic syndrome
(
MDS
) was performed to investigate the hematopoietic effects and the increase of neutrophils. The rhG-CSF was administered daily by intravenous infusion over 30 min. to 21 patients with
MDS
(
PARA
= 11, RAEB = 4, RAEB in T = 6). The dose was escalated stepwise from 50 to 400 microgram/m2 every week. Within one week to 26 days after commencement of rhG-CSF administration, the increases of absolute neutrophil counts in peripheral blood were observed in all patients. Treatment with rhG-CSF enhanced normal marrow myeloid cell differentiation and maturation in 3 of 9
PARA
patients and in 3 of 4 RAEB patients. None of patients changed to acute leukemia attributable to rhG-CSF, but one of RAEB patient and two of RAEB in T patients progressed to leukemic phase in 21 days or two months after treatment. Minor side effects or abnormal laboratory findings were observed in 3 patients (14.3%). These results suggested that treatment with rhG-CSF was well tolerated and effective for improving the neutropenia between 50 to 400 micrograms/m2 in patients with
MDS
.
...
PMID:[Clinical study of rhG-CSF (KRN8601) in patients with myelodysplastic syndrome]. 169 7
The presence of a transforming gene in the DNA of bone marrow cells from patients with
myelodysplastic syndrome
(
MDS
) was studied using an in vivo selection assay in which NIH 3T3 cells transfected with human DNA were injected into nude mice in order to observe the growth of the tumor. The transforming gene was present in 12 out of 18 cases. The Alu sequence was demonstrated in the tumor grown after injection of transfected NIH 3T3 cells from 10 patients. Among these 10 Alu sequences, the human N-ras oncogene was present in 3 cases. Analysis of nucleotide sequences of the exons of human N-ras oncogenes cloned from the tumors revealed a single point mutation of the codon encoding the 13th amino acid of exon 1 from guanine to cytosine in all 3 cases of
MDS
. A one-year follow-up study of these
MDS
cases showed that in the patients positive for the transforming gene, the disease state progressed from
PARA
, PASA to RAEB or from RAEB to acute leukemia in 6 out of 7 cases, while in the 6 negative patients, no change was observed in their disease states. It was considered that the mutation of the N-ras gene at the 13th amino acid codon of exon 1 was fairly specific to
MDS
and that presence of the transforming gene may be used for predicting the progress of the disease.
...
PMID:[Transforming gene in the preleukemic state]. 360 44